ヨーロッパのSJS/TEN治療市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2023 –2030 |
 市場規模（基準年） |
USD 1,686.96 Million |
 Market Size (Forecast Year) |
USD 2,737.34 Million |
 CAGR |
% |
| 主要市場プレーヤー |
>ヨーロッパのSJS/TEN治療市場、治療（薬物、サポートケア、入院、隔離、軟膏など）、診断（身体検査、皮膚生検、病歴、血液検査、培養など）、原因（特定の治療、感染症など）、投与経路（経口、非経口、局所など）、薬剤タイプ（ブランド薬とジェネリック薬）、治療領域（併用療法と単独療法）、患者タイプ（高齢者、成人、小児）、エンドユーザー（病院、専門クリニック、外来手術センター、在宅ケア環境など）、流通チャネル（小売薬局、直接入札など）別 - 2030年までの業界動向と予測。
ヨーロッパのSJS/TEN治療市場の分析と洞察
スティーブンス・ジョンソン症候群（SJS）と中毒性表皮壊死症（TEN）の治療市場は、これらの疾患が希少であるため、比較的小規模です。
ヨーロッパの SJS/TEN 治療市場は、薬物がこれらの症状の主な治療方法であるため、薬物が主流となっています。コルチコステロイド、静脈内免疫グロブリン (IVIG)、抗生物質は、SJS/TEN の治療に最も一般的に使用される薬剤です。
ヨーロッパのSJS/TEN治療市場は、2023年から2030年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に6.4％のCAGRで成長し、2022年の16億8,696万米ドルから2030年には27億3,734万米ドルに達すると分析しています。
ヨーロッパの SJS/TEN 治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームは、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2015 - 2020 にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
治療（投薬、サポートケア、入院、隔離、軟膏など）、診断（身体検査、皮膚生検、病歴、血液検査、培養など）、原因（特定の治療、感染症など）、投与経路（経口、非経口、局所など）、薬剤の種類（ブランド薬とジェネリック薬）、治療領域（併用療法と単独療法）、患者タイプ（高齢者、成人、小児）、エンドユーザー（病院、専門クリニック、外来手術センター、在宅ケア環境など）、流通チャネル（小売薬局、直接入札など） |
|
対象国 |
英国、フランス、ドイツ、イタリア、ロシア、スペイン、オランダ、デンマーク、スイス、スウェーデン、ポーランド、ノルウェー、フィンランド、ベルギー、トルコ、その他のヨーロッパ諸国 |
|
対象となる市場プレーヤー |
3M（米国）、カーディナルヘルス（米国）、BD（米国）、スミス・アンド・ネフュー（英国）、ノバルティスAG（スイス）、アムニール・ファーマシューティカルズLLC（米国）、アムジェン社（米国）、ファイザー社（米国）、コルゲート・パーモリーブ社（米国）、メルク社（米国）、メンリッケ・ヘルスケアAB（スウェーデン）、エクストリウム・ラボラトリーズ（米国）、シュルケ・アンド・マイヤー社（ドイツ）、ICPAヘルスプロダクツ社（インド）、パーデュー・ファーマLP（米国）、ユージア（オーロビンドファーマの子会社）、アドバケアファーマ（米国）など |
市場の定義
スティーブンス・ジョンソン症候群 (SJS) と中毒性表皮壊死症 (TEN) は、まれではありますが、通常は重篤な薬物反応によって起こる、生命を脅かす皮膚疾患です。これらの疾患は、皮膚の最上層がその下の層から分離し、痛みを伴う水疱や潰瘍を生じ、体の大部分に及ぶことがあります。SJS は皮膚のより小さな部分に影響を及ぼしますが、TEN は皮膚のより広い部分に影響を及ぼします。
SJS/TEN 治療の定義は、これらの症状を管理および治療するために設計された製品とサービスを指します。市場には、SJS/TEN の症状を緩和し、患者の生活の質を向上させるのに役立つ薬、療法、およびその他の治療法があります。SJS/TEN 治療薬市場には、症状を緩和し、根本的な原因を治療するために使用される多くの薬が含まれています。
ヨーロッパのSJS/TEN治療市場の動向
このセクションでは、市場の推進要因、利点、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
-
SJS/TENの有病率と発症率の増加
スティーブンス・ジョンソン症候群 (SJS) と中毒性表皮壊死症 (TEN) は、皮膚と粘膜に起こる重篤で生命を脅かす可能性のある病気です。SJS と TEN は病気の両極と考えられており、SJS はより軽症で、TEN はより重症です。これらの病気の特徴は、強い免疫反応により表皮 (皮膚の外側の層) が真皮 (皮膚の下の層) から分離することです。
スティーブンス・ジョンソン症候群 (SJS) と中毒性表皮壊死症 (TEN) は、表皮が真皮から分離する症状を特徴とする、まれではあるが重篤な皮膚疾患です。SJS/TEN の発症率は、年間 100 万人あたり約 1 人であると報告されています。しかし、近年、SJS/TEN の発症率と有病率に対する懸念が高まっています。
-
SJS/TEN治療薬開発の進歩
スティーブンス・ジョンソン症候群 (SJS) と中毒性表皮壊死症 (TEN) は、重篤で生命を脅かす可能性のある病気であり、迅速かつ積極的な治療が必要です。現在、SJS/TEN を治すことができる特定の薬や治療法はありませんが、薬剤開発の進歩により、罹患した患者に対する治療戦略と治療結果が改善されています。しかし、SJS/TEN 治療薬の開発に向けて、さまざまな臨床試験が行われています。
拘束
-
SJS/TENの治療に伴う高額な費用
SJS/TEN の治療費が高額になる主な理由の 1 つは、集中的かつ長期の治療が必要であることです。SJS/TEN の患者は、多くの場合、専門の火傷治療室に入院する必要があり、そこで皮膚科医、眼科医、集中治療専門医などの医療専門家チームから 24 時間体制で治療を受けます。入院は数週間、重症の場合は数か月かかることもあります。これにより、病院代や交通費、宿泊費、食費などの関連費用が高額になる可能性があります。
機会
-
SJS/TENに対する効果的かつ安全な治療法の開発
幹細胞移植は、損傷した皮膚や粘膜を健康な組織に置き換えることを目的とした新しいアプローチです。患者の皮膚から幹細胞を採取し、培養して損傷部位に再移植する自己幹細胞移植は、小規模な研究で有望な結果を示しています。
チャレンジ
- SJS/TENの治療薬承認に関する厳格な政府規制
SJS/TEN 治療の承認に関する厳格な政府規制は、米国食品医薬品局 (FDA) や欧州医薬品庁 (EMA) などの規制当局から SJS/TEN 治療の承認を得るために製薬会社とその医薬品が通過しなければならない複雑で厳格なプロセスに関連しています。
新薬の承認プロセスには通常、薬の安全性と有効性を評価するための人間を対象とした臨床試験の段階がいくつか含まれます。
最近の動向
- 2020年6月、欧州の大手医療技術企業であるBDは、非公開企業であるStraub Medical AGの買収を完了したことを発表しました。この買収により、同社はStraub Medical AGの貴重な専門知識と経験を獲得し、製品ポートフォリオを拡大しました。これにより、同社は市場で拡大し、成長することができます。
- 2019 年 1 月、Mölnlycke Health Care AB は MandJ Airlaid Products A/S を買収し、創傷ケア能力をさらに強化します。買収に伴い、MandJ とその従業員は Mölnlycke の不可欠な一部となります。この買収により、Mölnlycke は高度な創傷被覆材の製造に必要なエアレイド素材の供給の安定性が向上し、既存および将来の製品におけるイノベーションと製品開発を加速することで創傷ケア事業の成長が促進されます。これにより、同社は市場で拡大し、成長することができます。
ヨーロッパのSJS/TEN治療市場の範囲
ヨーロッパの SJS/TEN 治療市場は、治療、診断、原因、投与経路、薬剤の種類、療法の種類、患者の種類、エンド ユーザー、流通チャネルに基づいて、9 つの主要なセグメントに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コア アプリケーション領域とターゲット市場の違いを判断するのに役立ちます。
ヨーロッパの SJS/TEN 治療市場は、治療、診断、原因、投与経路、薬剤の種類、療法の種類、患者の種類、エンドユーザー、流通チャネルに基づいて 9 つの主要なセグメントに分類されます。
処理
- 医薬品
- サポートケア
- 軟膏
- 入院
- 分離
- その他
治療に基づいて、ヨーロッパのSJS/TEN治療市場は、薬物療法、サポートケア、入院、隔離、軟膏、その他に分類されます。
診断
- 身体検査
- 病歴
- 皮膚生検
- 血液検査
- 文化
- その他
診断に基づいて、ヨーロッパのSJS/TEN治療市場は、身体検査、皮膚生検、病歴、血液検査、培養、その他に分類されます。
原因
- 特定の治療
- 感染
- その他
原因に基づいて、ヨーロッパのSJS/TEN治療市場は、特定の治療、感染症、その他に分類されます。
投与経路
- オーラル
- 非経口
- 話題
- その他
投与経路に基づいて、ヨーロッパの SJS/TEN 治療市場は、経口、非経口、局所、その他に分類されます。
薬剤の種類
- ブランド
- ジェネリック
薬剤の種類に基づいて、ヨーロッパのSJS/TEN治療市場はブランド薬とジェネリック薬に分類されます。
治療の種類
- 単独療法
- 併用療法
治療の種類に基づいて、ヨーロッパの SJS/TEN 治療市場は、併用療法と単独療法に分類されます。
患者タイプ
- 小児科
- アダルト
- 老年病
患者タイプに基づいて、ヨーロッパの SJS/TEN 治療市場は、老年、成人、小児に分類されます。
エンドユーザー
- 病院
- 専門クリニック
- 外来手術センター
- 在宅ケア環境
- その他
エンドユーザーに基づいて、ヨーロッパの SJS/TEN 治療市場は、病院、専門クリニック、外来手術センター、在宅ケア環境、その他に分類されます。
流通チャネル
- 直接入札
- 小売薬局
- その他
流通チャネルに基づいて、ヨーロッパのSJS/TEN治療市場は、小売薬局、直接入札、その他に分類されます。
ヨーロッパのSJS/TEN治療市場の地域分析/洞察
ヨーロッパの SJS/TEN 治療市場は、治療、診断、原因、投与経路、薬剤の種類、療法の種類、患者の種類、エンドユーザー、流通チャネルに基づいて 9 つの主要なセグメントに分類されます。
この市場レポートで取り上げられている国は、英国、フランス、ドイツ、イタリア、ロシア、スペイン、オランダ、デンマーク、スイス、スウェーデン、ポーランド、ノルウェー、フィンランド、ベルギー、トルコ、その他のヨーロッパ諸国です。
SJS/TEN治療薬の生産増加、新興市場からの需要増加、ヘルスケア産業の拡大により、ドイツが優位に立つと予想されます。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。
競争環境とヨーロッパのSJS/TEN治療市場シェア分析
ヨーロッパの SJS/TEN 治療市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と幅、アプリケーションの優位性、および技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、ヨーロッパの SJS/TEN 治療市場への会社の重点にのみ関連しています。
ヨーロッパのSJS/TEN治療市場で活動している主要企業としては、3M（米国）、カーディナルヘルス（米国）、BD（米国）、スミス・アンド・ネフュー（英国）、ノバルティスAG（スイス）、アムニール・ファーマシューティカルズLLC（米国）、アムジェン社（米国）、ファイザー社（米国）、コルゲート・パーモリーブ社（米国）、メルク社（米国）、メンリッケ・ヘルスケアAB（スウェーデン）、エクストリウム・ラボラトリーズ（米国）、シュルケ・アンド・マイヤー社（ドイツ）、ICPAヘルスプロダクツ社（インド）、パーデュー・ファーマLP（米国）、eugia（オーロビンド・ファーマの子会社）、アドバケア・ファーマ（米国）などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE SJS/TEN TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 KEY TRENDS
4.2 COST OF TREATMENT
4.3 KEY PLAYERS STRATEGIES
4.4 LONG TERM GROWTH APPROACH
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DEMOGRAPHIC TRENDS
6.3 PATIENT FLOW DIAGRAM
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT
7.3 OPPORTUNITIES
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT
8 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANTIHISTAMINES
8.2.1.1 HYDROXYZINE
8.2.1.2 FEXOFENADINE
8.2.2 CORTICOSTEROID
8.2.2.1 DEXAMETHASONE
8.2.2.2 PREDNISOLONE
8.2.2.3 METHYLPREDNISOLONE
8.2.2.4 HYDROCORTISONE
8.2.2.5 OTHERS
8.2.3 ANTIBIOTICS
8.2.3.1 NAFCILLIN
8.2.3.2 GENTAMICIN
8.2.3.3 OTHERS
8.2.4 ANALGESICS
8.2.4.1 MORPHINE
8.2.4.2 FENTANYL CITRATE
8.2.4.3 OTHERS
8.2.5 ANTICOAGULANTS
8.2.6 ANTISEPTICS
8.2.6.1 CHLORHEXIDINE GLUCONATE
8.2.6.1.1 PERIOGARD
8.2.6.1.2 PERIDEX
8.2.6.1.3 AVAGARD
8.2.6.1.4 HIBICLENS
8.2.6.1.5 OTHERS
8.2.6.2 OCTENISEPT
8.2.6.3 POLYHEXANIDE SOLUTIONS
8.2.6.4 OTHERS
8.2.7 INTRAVENOUS IMMUNOGLOBULIN
8.2.8 CYCLOSPORINE
8.2.8.1 NEORAL
8.2.8.2 SANDIMMUNE
8.2.8.3 OTHERS
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)
8.2.10 OTHER TREATMENT
8.2.10.1 CYCLOPHOSPHAMIDE
8.2.10.2 N-ACETYLCYSTEINE
8.2.10.3 MONOCLONAL ANTIBODIES
8.2.10.4 THALIDOMIDE
8.3 SUPPORT CARE
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES
8.3.2 PAIN MANAGEMENT
8.3.2.1 LIDOCAINE
8.3.2.2 OTHERS
8.3.3 NUTRITION SUPPORT
8.3.4 ORAL CARE
8.3.5 PLASMAPHERESIS
8.3.6 BANDAGES
8.3.6.1 BIOLOGICAL DRESSING
8.3.6.1.1 ALLOGRAFT
8.3.6.1.2 XENOGRAFT
8.3.6.1.3 HOMOGRAFT
8.3.6.1.4 OTHERS
8.3.6.2 BIOSYNTHETIC DRESSING
8.3.6.3 SILVER IMPREGNATED DRESSING
8.4 HOSPITALIZATION
8.5 ISOLATION
8.6 OINTMENTS
8.6.1 BENZOCAINE
8.6.2 AMERICAINE
8.6.3 ANBESOL
8.6.4 CHIGGEREX PLUS
8.6.5 OTHERS
8.7 OTHERS
9 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PHYSICAL EXAM
9.3 SKIN BIOPSY
9.4 MEDICAL HISTORY
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT
9.5.2 ERYTHROCYTE SEDIMENTATION RATE
9.5.3 COAGULATION STUDIES
9.5.4 UREA AND ELECTROLYTES
9.5.5 LIVER FUNCTION TEST
9.6 CULTURES
9.7 OTHERS
10 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 SPECIFIC TREATMENT
10.3 INFECTION
10.4 OTHERS
11 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 SUBCUTANEOUS
11.3.3 OTHERS
11.4 TOPICAL
11.4.1 OINTMENTS
11.4.2 SOLUTION
11.4.3 CREAMS
11.4.4 OTHERS
11.5 OTHERS
12 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 NEORAL
12.2.2 SANDIMMUNE
12.2.3 VISTARIL
12.2.4 DURAMORPH
12.2.5 FENTORA
12.2.6 ENBREL
12.2.7 OTHERS
12.3 GENERIC
13 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 COMBINATION THERAPY
13.3 MONOTHERAPY
14 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.2.1 FEMALE
14.2.2 MALE
14.3 ADULT
14.3.1 FEMALE
14.3.2 MALE
14.4 PEDIATRIC
15 EUROPE SJS/TEN TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTER
15.5 HOMECARE SETTING
15.6 OTHERS
16 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.2.1 HOSPITAL ASSOCIATED PHARMACIES
16.2.2 DRUG STORE
16.2.3 ONLINE PHARMACIES
16.3 DIRECT TENDERS
16.4 OTHERS
17 EUROPE SJS/TEN TREATMENT MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 DENMARK
17.1.10 NETHERLANDS
17.1.11 SWITZERLAND
17.1.12 SWEDEN
17.1.13 POLAND
17.1.14 NORWAY
17.1.15 FINLAND
17.1.16 REST OF EUROPE
18 EUROPE SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 NOVARTIS AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 MERCK & CO., INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 AMNEAL PHARMACEUTICAL LLC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 AMGEN INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ADVACARE PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 CARDINAL HEALTH
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 COLGATE-PALMOLIVE COMPANY
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ICPA HEALTH PRODUCTS LTD
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 3M
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 MOLNLYCKE HEALTH CARE AB.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 PURDUE PHARMA L.P.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 SCHULKE & MAYR GMBH
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 SMITH + NEPHEW
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 XTTRIUM LABORATORIES
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表のリスト
TABLE 1 EUROPE SJS/TEN TREATMENT MARKET, PATENT ANALYSIS
TABLE 2 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 12 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 13 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 16 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 18 EUROPE HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 22 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 24 EUROPE PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 29 EUROPE CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 41 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 45 EUROPE GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 52 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 EUROPE HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 EUROPE AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 64 EUROPE DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 68 EUROPE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 70 EUROPE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 72 EUROPE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 73 EUROPE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 74 EUROPE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 75 EUROPE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 76 EUROPE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 77 EUROPE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 78 EUROPE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 EUROPE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 80 EUROPE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 83 EUROPE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 84 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 EUROPE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 EUROPE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 EUROPE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 91 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 92 EUROPE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 93 EUROPE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 94 EUROPE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 EUROPE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 GERMANY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 98 GERMANY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 GERMANY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 100 GERMANY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 101 GERMANY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 102 GERMANY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 103 GERMANY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 104 GERMANY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 105 GERMANY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 106 GERMANY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 107 GERMANY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 108 GERMANY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 GERMANY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 110 GERMANY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 112 GERMANY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 114 GERMANY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 GERMANY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 GERMANY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 GERMANY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 GERMANY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 GERMANY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 121 GERMANY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 122 GERMANY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 GERMANY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 124 GERMANY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 125 GERMANY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 126 GERMANY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 FRANCE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 128 FRANCE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 FRANCE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 130 FRANCE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 131 FRANCE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 132 FRANCE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 135 FRANCE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 136 FRANCE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 137 FRANCE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 138 FRANCE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 FRANCE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 140 FRANCE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 141 FRANCE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 142 FRANCE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 143 FRANCE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 144 FRANCE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 FRANCE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 FRANCE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 149 FRANCE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 FRANCE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 151 FRANCE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 152 FRANCE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 153 FRANCE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 154 FRANCE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 FRANCE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 FRANCE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 U.K. SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 158 U.K. MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 U.K. ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 160 U.K. CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 161 U.K. ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 162 U.K. ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 163 U.K. ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 164 U.K. CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 165 U.K. CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 166 U.K. OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 167 U.K. SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 168 U.K. PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 U.K. BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 170 U.K. BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 171 U.K. OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 172 U.K. SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 173 U.K. BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 174 U.K. SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 175 U.K. SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 176 U.K. PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 U.K. TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 U.K. SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 181 U.K. SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 182 U.K. GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 183 U.K. ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 184 U.K. SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 U.K. SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 U.K. RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 ITALY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 188 ITALY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 189 ITALY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 190 ITALY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 ITALY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 192 ITALY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 193 ITALY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 194 ITALY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 195 ITALY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 196 ITALY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 197 ITALY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 198 ITALY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 199 ITALY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 200 ITALY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 ITALY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 202 ITALY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 203 ITALY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 204 ITALY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 205 ITALY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 206 ITALY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 207 ITALY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 208 ITALY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 209 ITALY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 ITALY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 211 ITALY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 212 ITALY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 213 ITALY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 214 ITALY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 215 ITALY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 216 ITALY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 217 SPAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 218 SPAIN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 219 SPAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 220 SPAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 SPAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 222 SPAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 223 SPAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 224 SPAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 225 SPAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 226 SPAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 227 SPAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 228 SPAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 229 SPAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 230 SPAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 SPAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 232 SPAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 233 SPAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 234 SPAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 235 SPAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 236 SPAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 SPAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 238 SPAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 SPAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 SPAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 242 SPAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 243 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 SPAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 245 SPAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 257 RUSSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 RUSSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 274 RUSSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 275 RUSSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 276 TURKEY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 277 TURKEY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 278 TURKEY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 279 TURKEY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 280 TURKEY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 TURKEY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 282 TURKEY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 283 TURKEY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 284 TURKEY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 285 TURKEY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 286 TURKEY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 288 TURKEY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 289 TURKEY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 290 TURKEY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 TURKEY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 292 TURKEY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 293 TURKEY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 294 TURKEY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 295 TURKEY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 296 TURKEY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 TURKEY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 298 TURKEY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 299 TURKEY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 300 TURKEY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 301 TURKEY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 302 TURKEY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 303 TURKEY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 TURKEY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 TURKEY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 306 BELGIUM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 314 BELGIUM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 315 BELGIUM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 316 BELGIUM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 317 BELGIUM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 318 BELGIUM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 319 BELGIUM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 320 BELGIUM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 321 BELGIUM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 322 BELGIUM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 323 BELGIUM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 324 BELGIUM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 BELGIUM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 326 BELGIUM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 327 BELGIUM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 BELGIUM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 BELGIUM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 330 BELGIUM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 331 BELGIUM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 332 BELGIUM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 333 BELGIUM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 BELGIUM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 BELGIUM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 336 DENMARK SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 337 DENMARK MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 338 DENMARK ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 339 DENMARK CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 340 DENMARK ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 341 DENMARK ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 342 DENMARK ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 343 DENMARK CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 DENMARK CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 345 DENMARK OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 346 DENMARK SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 347 DENMARK PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 348 DENMARK BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 349 DENMARK BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 350 DENMARK OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 351 DENMARK SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 352 DENMARK BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 353 DENMARK SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 354 DENMARK SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 355 DENMARK PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 356 DENMARK TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 357 DENMARK SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 DENMARK BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 DENMARK SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 360 DENMARK SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 361 DENMARK GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 362 DENMARK ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 363 DENMARK SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 364 DENMARK SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 365 DENMARK RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 371 NETHERLANDS ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 372 NETHERLANDS ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 374 NETHERLANDS CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 375 NETHERLANDS OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 378 NETHERLANDS BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 379 NETHERLANDS BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 381 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 382 NETHERLANDS BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 384 NETHERLANDS SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 385 NETHERLANDS PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 392 NETHERLANDS ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 393 NETHERLANDS SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 394 NETHERLANDS SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 395 NETHERLANDS RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 396 SWITZERLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 397 SWITZERLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 399 SWITZERLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 400 SWITZERLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 406 SWITZERLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 407 SWITZERLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 409 SWITZERLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 410 SWITZERLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 418 SWITZERLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 SWITZERLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 420 SWITZERLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 421 SWITZERLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 422 SWITZERLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 423 SWITZERLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 424 SWITZERLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 425 SWITZERLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 426 SWEDEN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 427 SWEDEN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 430 SWEDEN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 431 SWEDEN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 435 SWEDEN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 436 SWEDEN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 438 SWEDEN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 439 SWEDEN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 450 SWEDEN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 451 SWEDEN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 452 SWEDEN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 453 SWEDEN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 454 SWEDEN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 455 SWEDEN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 456 POLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 457 POLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 458 POLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 459 POLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 460 POLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 461 POLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 462 POLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 463 POLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 464 POLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 465 POLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 466 POLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 467 POLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 468 POLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 469 POLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 470 POLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 471 POLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 472 POLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 473 POLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 474 POLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 475 POLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 476 POLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 477 POLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 478 POLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 POLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 480 POLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 481 POLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 482 POLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 483 POLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 484 POLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 485 POLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 486 NORWAY SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 487 NORWAY MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 488 NORWAY ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 489 NORWAY CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 490 NORWAY ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 491 NORWAY ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 492 NORWAY ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 493 NORWAY CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 494 NORWAY CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 495 NORWAY OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 496 NORWAY SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 497 NORWAY PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 498 NORWAY BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 499 NORWAY BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 500 NORWAY OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 501 NORWAY SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 502 NORWAY BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 503 NORWAY SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 504 NORWAY SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 505 NORWAY PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 506 NORWAY TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 507 NORWAY SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 508 NORWAY BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 509 NORWAY SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 510 NORWAY SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 511 NORWAY GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 512 NORWAY ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 513 NORWAY SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 514 NORWAY SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 515 NORWAY RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 516 FINLAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 517 FINLAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 518 FINLAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 519 FINLAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 520 FINLAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 521 FINLAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 522 FINLAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 523 FINLAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 524 FINLAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 525 FINLAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 526 FINLAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 527 FINLAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 528 FINLAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 529 FINLAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 530 FINLAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 531 FINLAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 532 FINLAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 533 FINLAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 534 FINLAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 535 FINLAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 536 FINLAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 537 FINLAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 538 FINLAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 539 FINLAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 540 FINLAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 541 FINLAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 542 FINLAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 543 FINLAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 544 FINLAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 545 FINLAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 546 REST OF EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE SJS/TEN TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SJS/TEN TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SJS/TEN TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SJS/TEN TREATMENT MARKET
FIGURE 14 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022
FIGURE 15 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022
FIGURE 19 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 EUROPE SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2022
FIGURE 23 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 25 EUROPE SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 26 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 EUROPE SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022
FIGURE 31 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 EUROPE SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022
FIGURE 35 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)
FIGURE 37 EUROPE SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 38 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022
FIGURE 39 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 40 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 41 EUROPE SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 42 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2022
FIGURE 43 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 EUROPE SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 EUROPE SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 EUROPE SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 51 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 52 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 EUROPE SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 EUROPE SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)
FIGURE 55 EUROPE SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
